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Background: Current guidelines for anticoagulation during left-sided procedures recommend the
administration of unfractionated heparin (UFH) with an initial bolus of 50e100 U/kg, followed by
continuous infusion to maintain an activated clotting time (ACT)  300 s. Our objective was to compare
the effectiveness of this standard regimen (100 U/kg bolus) to a more aggressive approach (200 U/kg
bolus).
Methods: We collected data on a series of consecutive patients undergoing left sided ablation proced-
ures. Patients with an INR 2.0 on the day of the procedure were excluded. Procedural anticoagulation
was performed using one of two UFH regimens: 1) 100 U/kg bolus, followed by 10 U/kg/hour infusion or
2) 200 U/kg bolus, followed by 20 U/kg/hour infusion. ACT was measured 10 min after the second bolus
and then controlled every 20 min. Heparin was titrated throughout the procedure to maintain an ACT
300e400 s.
Results: 145 consecutive patients were included in the study: 34 received an initial bolus of 100 U/kg and
111 received 200 U/kg. The mean time required to reach an ACT 300 s was 15.25 min (95% CI 12.97
e17.03) in the 200 U/kg group and 51.23 min (95% CI 40.65e61.81) in the 100 U/kg group (p < 0.001).
There was no difference between groups with regard to thromboembolic or hemorrhagic complications.
Conclusion: Current anticoagulation guidelines for left-sided ablation procedures almost universally fail
to achieve an initial ACT 300 s. A 200 U/kg heparin bolus is much more effective to promptly reach the
target ACT, with a low rate of overshoot.
Copyright © 2016, Indian Heart Rhythm Society. Production and hosting by Elsevier B.V. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Over the past decade, the number of patients undergoing left-
sided ablation procedures increased dramatically, mainly because
of the advent of pulmonary vein isolation as an effective treatment
for atrial ﬁbrillation (AF). In experienced centers, the risk of major
complication associated with left sided interventions is relatively
low. Thromboembolic complications nevertheless happen in
approximately 1% of procedures [1]. The potentially dramatic
consequences of ischemic strokes make them one of the most
feared adverse events related to ablation procedures involving
systemic circulation.ooke, 3001, 12e avenue Nord,
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sided ablation procedures in order to minimize the risk of throm-
boembolic events. As such, procedural anticoagulation with
unfractionated heparin (UFH) is universally recommended in order
to avoid thrombus formation while catheters are maneuvered in
the systemic circulation. For AF ablation, current guidelines state
that heparin should be titrated to maintain an activated clotting
time of (ACT) 300e400 s. However, the dose of heparin to be
administered as a bolus and the rate of infusion are not clearly
deﬁned. While the 2007 HRS/EHRA/ECAS guidelines recommended
a 100 U/kg bolus, followed by a 10 U/kg/hour infusion, the 2012
update of the same guidelines makes no mention of the optimal
initial UFH dosage [2].
Among effective strategies to prevent thromboembolic compli-
cations, targeting a higher ACT value [3] and giving UFH prior to
left-sided access [4] are know to reduce spontaneous echo contrast
as well as thrombus formation on catheters. These ﬁndings shouldElsevier B.V. This is an open access article under the CC BY-NC-ND license (http://
ith a new anticoagulation regimen for patients undergoing left-sided
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efﬁcient and reproducible therapeutic ACTs early into the proced-
ure. In our experience, the 100 U/kg bolus followed by a 10 U/kg/
hour infusion is ineffective at reaching an initial ACT >300 s, which
exposes patients to a signiﬁcant delay in anticoagulation, hence
potentially increasing thromboembolic complications.2. Methods
This is a single-center pre/post-test prospective study of
consecutive patients undergoing left-sided ablation procedures
between February 2012 and January 2014. The study was approved
by the Institutional Committee on Human Research. Patients were
included if all ACT's were documented throughout the procedure
and were excluded if they were on warfarin with an INR 2.
The ﬁrst patients of our series (pre-test) received a 100 U/kg
UFH bolus prior to transeptal punctures or immediately following
arterial access, followed by a 10 U/kg/hour infusion. The following
patients (post-test) received a 200 U/kg bolus, followed by a 20 U/
kg/hour infusion. Initial ACT was measured immediately following
transeptal or arterial access, and was retested every 20 min using
an ACT Plus Automated Coagulation Timer System (Medtronic,
Minneapolis MN United States). Infusion was then titrated in a
similar fashion in both groups targeting an ACT between 300 and
400 s. ACT's were recorded until the last catheter was pulled from
the left-sided cavities. All ACT values were documented, as well as
the time at which they were obtained. Additional UFH boluses
required to reach the target ACT were also documented but left to
the discretion of the operator.
Warfarinwas discontinued 48e96 h before the procedure, while
NOACswere stopped 24 h prior. Since atrial ﬁbrillation ablation in is
performed without stopping warfarin in our center and given the
fact that patients with an INR 2 were excluded form the study,
most patients undergoing atrial ﬁbrillation ablation in this study
were anticoagulated with a NOAC. After the procedure, in patients
previously treated with a NOAC, oral anticoagulation was restarted
with the same agent 6 h after sheath removal. Patients on warfarin
with an INR <2were started on IV heparin or low-molecular weight
heparin 6 h after sheath removal and continued until INR was
therapeutic.
Major procedural complications were recorded up to 30 days
after the procedure. Hemorrhagic complications included bleeding
requiring transfusion or prolonging hospitalization, as well as
pericardial effusion requiring drainage. Thromboembolic compli-
cations included neurologic, systemic and pulmonary embolic
events.
Primary endpoint was the time to ﬁrst ACT 300 s, T0 repre-
senting the time at which the ﬁrst UFH bolus was given. Secondary
endpoints included the proportion of patients with therapeutic
(300e400 s) and supra-therapeutic (450 s) ACTs at each time
point during the procedure, as well as a pre-speciﬁed analysis of
patients according to weight quartile.2.1. Statistical analysis
Continuous variables were compared using non-parametric
Mann-Whitney test when data analysis suggested a non-normal
distribution, and Student t-test when they were normally distrib-
uted. Proportions were compared using Chi-Square or Fisher's
exact tests as appropriate. A bilateral p-value < 0.05was considered
statistically signiﬁcant. All analyses were performed using SAS
University Edition (SAS Institute Inc. North Carolina, USA).Please cite this article in press as: Dussault C, et al., Real-life experience w
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3.1. Baseline characteristics
A total of 145 patients met inclusion/exclusion criteria. The ﬁrst
34 patients received a 100 U/kg UFH bolus, while the following 111
patients received the 200 U/kg bolus. Baseline characteristics as
well as proportion of patients treated with warfarin, novel oral
anticoagulants (NOACs) or no anticoagulant prior to the interven-
tion are similar between groups (Table 1).
The majority of patient underwent either pulmonary vein
isolation or left-sided (atypical) atrial ﬂutter ablation. Remaining
patients either had ventricular arrhythmia ablation or ablation for
supraventricular tachycardia originating from the left atrium
(Table 2). Procedural time was signiﬁcantly longer in the 200 U/kg
group (183.8 min - 95% CI 166.2e201.4) compared to the 100 U/kg
group (157.2 mine95% CI 147.2e167.2) (p-value 0.0108).
Regarding heparin dosages, while the initial bolus was higher in
the 200 U/kg group, additional boluses of UFH were signiﬁcantly
higher in the 100 U/kg group (1122 U vs 5754 U, p< 0.001) (Table 2).
Mean ACT's were signiﬁcantly higher in the 200 U/kg group
throughout the procedure, but the difference reached statistical
signiﬁcance only for the ﬁrst four ACT measurements (Fig. 1).
3.2. Primary outcome: time to ﬁrst ACT 300 s
Subjects in the 200 U/kg group took amean of 15.25min (95% C.I
12.97e17.03) to reach an ACT  300 s, while it took an average of
51.23 min (95% C.I 40.65e61.81) in the 100 U/kg group (Table 3).
The difference was statistically signiﬁcant (p < 0.0001). Moreover,
only 5.9% (n ¼ 2) of subjects in the 100 U/kg group had an initial
ACT 300 s, while 89,2% (n¼ 99) of subjects in the 200 U/kg group
did. The difference was statistically signiﬁcant (p < 0.0001).
3.3. Secondary outcomes
The proportion of patients with a therapeutic ACT (300e400 s)
was signiﬁcantly higher in the 200 U/kg group for the ﬁrst two ACT
measurements (Fig. 2). There was no signiﬁcant difference in the
proportion of patients with supratherapeutic ACT (>450 s)
throughout the procedure between the groups (Fig. 3). Among
patients with an initial ACT >450 s in the 200 U/kg group (n ¼ 14),
the mean INR was signiﬁcantly higher (1.50, 95% CI 1.37e1.63)
compared to patients with an initial ACT < 450 s in this same 200 U/
kg group (1.12, 95% CI 1.09e1.16) (p value < 0.0001).
An analysis of variance was also performed on the mean initial
ACT according to weight quartile in both groups. We found no
signiﬁcant difference in mean initial ACTs betweenweight quartiles
for both the 100 U/kg group (p ¼ 0.48) and 200 U/kg group
(p ¼ 0.17) (Fig. 4).
Finally, there was no signiﬁcant difference in hemorrhagic (8.8%
100 U/kg vs 3.4% 200 U/kg p¼ 0.7) or ischemic (0% 100 U/kg vs 0.8%
200 U/kg p ¼ 1) complications at 30 days between groups. When
looking speciﬁcally at hemorrhagic complications, in the 200 U/kg
group, 3 patients had pericardial effusions, 1 associated with tam-
ponade requiring periprocedural percutaneous drainage in the
electrophysiology lab and 2 presenting in the following weeks with
symptomatic pericardial effusion requiring elective drainage. 4
other patients had groin hematoma, 1 requiring transfusion of 2
units packed red cells and 3 prolonging their hospital stay by 2e3
days due to pain. Finally, one patient died suddenly of pulseless
electrical arrest <24 h following VT ablation of unknown cause. Of
note, no hemorrhagic etiology was identiﬁed in that patient
following head and thoracoabdominal CT and transthoracic echo-
cardiogram. In the 100 U/kg group, 1 patient had an access relatedith a new anticoagulation regimen for patients undergoing left-sided
http://dx.doi.org/10.1016/j.ipej.2016.10.011
Table 1
Baseline characteristics.
100 U/kg (n ¼ 34) 200 U/kg (n ¼ 111) p value
Age (years) 60.4 ± 11.9 59.4 ± 12.9 0.59
Male Sex (%) 64.7 (22) 70 (78) 0.55
Baseline INR 1.2 ± 0.2 1.16 ± 0.2 0.35
BMI 28.4 ± 7.2 28.9 ± 5.8 0.41
Weight (kg) 81.7 ± 24.3 86.1 ± 20.8 0.35
Creatinine Clearance (ml/min) 90.3 ± 44.9 85.6 ± 25.9 0.81
Warfarin (%) 9 (3) 12.6 (14) 0.76
NOAC (%) 41 (14) 56.8 (63) 0.32
No anticoagulant (%) 50 (17) 20.6 (34) 0.07
Warfarin was discontinued 48e96 h prior to the procedure.
Novel anticoagulants (NOAC) were discontinued 24 h prior to the procedure.
Table 2
Procedural data.
100 U/kg (n ¼ 34) 200 U/kg (n ¼ 111) p value
Type of procedure (%)
- Atrial ﬁbrillation/Atypical ﬂutter 58.8 (20) 76.6 (85) 0.051
- Ventricular Tachycardia/PVC 35.3 (12) 18.0 (20) 0.056
- SVT (AT/left-sided pathway) 5.9 (2) 5.4 (6) 1.000
Procedure duration (mins) 183.8 (50.4) 157.2 (53.2) 0.0108
Heparin Bolus e Initial (U) 8385 ± 2418 17370 ± 40722 <0.001
Heparin Bolus e Additional (U) 5754 ± 1035 1122 ± 1302 <0.001
SVT: Supraventricular tachycardia.
PVC: Premature ventricular contraction.
Fig. 1. Mean ACT (secs) with standard deviation throughout the procedure.
Table 3
Time to ﬁrst ACT 300 s.
100 U/kg (n ¼ 34) 200 U/kg (n ¼ 111) p value
Time (mins) 15.3 (95% CI 13.0e17.0) 51.2 (95% CI 40.7e61.8) <0.001
T0 ¼ Time of ﬁrst unfractionated heparin bolus.
Fig. 2. Proportion of patients with an ACT 300e400 s.
Fig. 3. Proportion of patients with a supratherapeutic ACT (>450 s).
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drainage 24 h after the procedure. Finally, among patients who
experienced an hemorrhagic complication in the 200 U/kg group
the mean initial ACT was 397.33 (Range 319e474 s).
4. Discussion
This study shows that current recommendations to administer
100 U/kg initial UFH bolus followed by a 10 U/kg/hour infusion
almost universally fails to reach a therapeutic ACT on the initialPlease cite this article in press as: Dussault C, et al., Real-life experience w
ablation procedures, Indian Pacing and Electrophysiology Journal (2016),measurement. Using a higher initial UFH bolus (200 U/kg) and
infusion rate (20 U/kg/hour) allows reaching a therapeutic ACT
signiﬁcantly faster than standard dosages. Quantitatively, patients
in the standard treatment arm (100 U/kg bolus) spent 35 moreith a new anticoagulation regimen for patients undergoing left-sided
http://dx.doi.org/10.1016/j.ipej.2016.10.011
Fig. 4. Initial ACT according to weight quartile. When divided according to weight
quartile (lower to higher weight) an analysis of variance conﬁrmed the absence of
signiﬁcant difference in the mean initial ACT for both the 100 U/kg and 200 U/kg group
across quartiles.
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200 U/kg group. While this study was not underpowered to assess
clinical outcomes, this period of time is probably clinically signiﬁ-
cant and could represent a critical period for the formation of
thrombus on catheters and sheaths, which could lead to throm-
boembolic complications. Previous studies showing increase in
spontaneous echo contrast and catheter thrombi formation in pa-
tients with less intense anticoagulation (250e300 s vs > 300 s) [3]
and delayed administration of UFH (before vs after transseptal ac-
cess) support this assumption [4]. The fact that additional boluses
of UFHwere signiﬁcantly higher in the 100 U/kg group compared to
the 200 U/kg group also suggests that the smaller dosage is inef-
fective at promptly reaching the target ACT, leading to more ad-
justments by the operator throughout the procedure. Procedural
time was signiﬁcantly longer in the 200 U/kg group compared to
the 100 U/kg group. This ﬁnding is most likely related to a higher
number of patients undergoing SVT ablation in the 100 U/kg group.
Even though numbers are small, these procedures are usually much
shorter that AF or VT ablations, which could have inﬂuenced the
mean procedural time.
Unfractionated heparin has a distribution volume of 40e70 ml/
kg that is proportional to blood volume. As obese patients have a
higher blood volume, it is accepted that they generally require
higher heparin doses in order to reach therapeutic ACT. This is why
weight-based nomograms are known to be more efﬁcient at
reaching target values of anticoagulation with UFH [6]. This was
conﬁrmed in the present study by the ﬁnding that initial mean ACT
was similar between weight quartile for both the 100 U/kg and
200 U/kg groups. This remained true even with very overweight
patients. The heaviest patient in the 200 U/kg group weighted
130 kg and received and initial bolus of 26000 units of UFH. His ﬁrst
ACT following the bolus was only 290 s.
Although our study was not powered to draw conclusions on
clinical endpoints, a 200 U/kg bolus followed by a 20 U/kg/hour
infusion of UFH for left-sided ablation procedures appears to be
safe, with similar 30 days hemorrhagic and ischemic complications.
A limitation of this study is that patients with a therapeutic INR
were excluded from the analysis. While many patients with higher
baseline thromboembolic risk now undergo the ablation procedure
with therapeutic INR, a 200 U/kg UFH bolus cannot be recom-
mended in this population because of a known interaction between
therapeutic INR and ACT response to UFH [5]. As NOACs are now
considered the standard of care to prevent thromboembolicPlease cite this article in press as: Dussault C, et al., Real-life experience w
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with warfarin is decreasing steadily. As the current practice is to
withhold NOACs 24e48 h prior to ablation procedures, the results
of our study apply to this growing population. While studies have
evaluated the safety of performing pulmonary vein isolation in
patients without interruption of NOACs, their results are somewhat
conﬂicting.
It was found that 11.7% of patients in the 200 U/kg group had an
initial ACT >450 s. While there was no statistically signiﬁcant dif-
ference between this proportion and the 2.9% from the 100 U/kg
group, this could be the result of a small sample size and reﬂect a
lack of power. While this might represent an argument against
using a higher initial heparin bolus to prevent supratherapeutic
ACTs, it is worth noting that the subgroup of patients with an initial
ACT >450 s in the 200 U/kg group had a signiﬁcantly higher
baseline INR than their counterparts with an initial ACT <450 s. This
ﬁnding is consistent with previous studies describing an increased
response to UFH in patients with elevated baseline INR. Until
further data are available, limiting the higher initial heparin bolus
strategy to patients with a normal baseline INR seems reasonable.
Finally, even though there was no formal protocol to adjust
heparin infusion throughout the procedure, ablations were per-
formed by only 3 operators from a single center, limiting major
management variations between patients.
5. Conclusions
Anticoagulation with UFH represents one of the cornerstone
strategies to reduce thromboembolic complications during left-
sided ablation procedures. The current standard of care of 100 U/
kg UFH bolus followed by a 10 U/kg/hour infusion is ineffective at
promptly reaching a target ACT of 300e400 s. A strategy using a
higher heparin dosage, with an initial bolus of 200 U/kg followed by
a 20 U/kg/hour infusion was signiﬁcantly more effective at rapidly
reaching a therapeutic ACT in patients undergoing left-sided abla-
tion procedure, without signiﬁcant increase in hemorrhagic com-
plications. Before incorporating this strategy in clinical practice,
larger clinical studies assessing the impact of this regimen on
speciﬁc safety clinical endpoints will be necessary.
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